Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Jennifer B. Green et al.|The Lancet|2018Cited by 1.8k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Chih‐Chin Liu et al.|The Lancet|2022Cited by 969
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without DiabetesGerasimos Filippatos, Stefan D. Anker, Javed Butler et al.|Circulation|2022Cited by 126
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes MellitusAbhinav Sharma, Christopher B. Granger, Neha J. Pagidipati et al.|Circulation|2020Cited by 108
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 DiabetesMichelle D. Kelsey, Neha J. Pagidipati, Adam J. Nelson et al.|Journal of the American College of Cardiology|2022Cited by 95